AN2 Therapeutics (ANTX) Gains from Sales and Divestitures (2024 - 2026)
AN2 Therapeutics (ANTX) reported Gains from Sales and Divestitures of $282413.0 for Q1 2026, up 143.54% year-over-year from $115962.0 in Q1 2025, and down 4.39% quarter-over-quarter from $295368.0 in Q4 2025.
AN2 Therapeutics (ANTX) Gains from Sales and Divestitures (2024 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 3 years of Gains from Sales and Divestitures data on file, last reported at $282413.0 in Q1 2026.
- Gains from Sales and Divestitures for Q1 2026 came in at $282413.0, up 143.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $282413.0 (up 143.54% YoY), and the FY2025 annual result was $295368.0, up 638.36% from the prior year.
- Gains from Sales and Divestitures eased to $282413.0 in Q1 2026 per ANTX's latest filing, from $295368.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $295368.0 in Q4 2025 and troughed at $13377.0 in Q2 2024.
- A 3-year average of $147361.0 and a median of $133434.0 in 2025 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2025 and 2026: Gains from Sales and Divestitures jumped 1028.1% in 2025, then soared 143.54% in 2026.
- A 3-year view of Gains from Sales and Divestitures shows it stood at $40003.0 in 2024, then jumped by 638.36% to $295368.0 in 2025, then slipped by 4.39% to $282413.0 in 2026.
- Business Quant data shows ANTX's Gains from Sales and Divestitures at $282413.0 in Q1 2026, $295368.0 in Q4 2025, and $253351.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 282,413.00 |
| Mar 31, 2026 | 282,413.00 |
| Dec 31, 2025 | 295,368.00 |
| Dec 31, 2025 | 295,368.00 |
| Sep 30, 2025 | 253,351.00 |
| Sep 30, 2025 | 253,351.00 |
| Jun 30, 2025 | 150,906.00 |
| Jun 30, 2025 | 150,906.00 |
| Mar 31, 2025 | 115,962.00 |
| Mar 31, 2025 | 115,962.00 |
| Dec 31, 2024 | 40,003.00 |
| Dec 31, 2024 | 40,003.00 |
| Sep 30, 2024 | 27,508.00 |
| Sep 30, 2024 | 27,508.00 |
| Jun 30, 2024 | 13,377.00 |
| Jun 30, 2024 | 13,377.00 |